Loading...
XJPX2395
Market cap445mUSD
Jan 22, Last price  
1,674.00JPY
1D
-0.65%
1Q
34.78%
Jan 2017
185.67%
Name

Shin Nippon Biomedical Laboratories Ltd

Chart & Performance

D1W1MN
XJPX:2395 chart
P/E
12.60
P/S
2.63
EPS
132.86
Div Yield, %
2.99%
Shrs. gr., 5y
—
Rev. gr., 5y
11.05%
Revenues
26.45b
+5.42%
12,295,730,00013,805,373,00017,289,403,00019,647,248,00019,540,215,00019,050,317,00017,371,947,00015,273,969,00017,154,051,00016,926,397,00017,835,036,00014,750,072,00017,244,496,00016,600,550,00015,658,678,00014,561,084,00015,110,548,00017,748,482,00025,090,903,00026,450,468,000
Net income
5.53b
-8.73%
-472,444,000267,412,000543,769,000599,874,000-205,549,000534,529,000-1,442,021,000-3,304,109,000-1,152,876,000-754,991,000-1,385,737,0002,646,136,000-915,938,000-3,555,948,0001,950,307,0002,550,379,0003,661,855,0007,127,629,0006,060,057,0005,531,261,000
CFO
2.11b
-47.38%
1,063,636,000755,051,000448,686,0003,166,398,000868,691,0001,743,584,000306,770,000-1,033,185,00090,290,000-1,620,133,000-2,156,044,000-3,339,930,000-849,807,0001,344,254,0002,892,655,0003,018,289,0004,746,687,0005,952,778,0004,004,019,0002,106,732,000
Dividend
Mar 28, 20250 JPY/sh

Profile

Shin Nippon Biomedical Laboratories, Ltd., a contract research organization, provides drug discovery and development services in Japan and internationally. It offers pre-clinical laboratory services, such as good laboratory practice inspections; general and specific toxicity studies; pathological examinations; PK/PD of biopharmaceuticals, immunotoxicity tests, and antibody production; reproductive and developmental toxicity studies; pharmacology and pharmacological efficacy studies; and imaging services. The company also engages in the establishment and validation of analytical methods, analysis of biological samples, and calculation of pharmacokinetic parameters; and provides absorption, distribution, metabolism, and excretion studies using radioisotope-labeled compounds. In addition, it provides site management organization services for clinical trials; clinical contract research organization services; and translational research services, including research and development of nasal delivery systems, nucleic acid adjuvants, and regenerative medicines. The company was founded in 1957 and is headquartered in Tokyo, Japan.
URL
https://www.snbl.co.jp/
IPO date
Mar 08, 2004
Employees
1,360
Domiciled in
JP
Incorporated in
JP

Valuation

Title
JPY in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2024‑032023‑032022‑032021‑032020‑032019‑032018‑032017‑032016‑032015‑03
Income
Revenues
26,450,468
5.42%
25,090,903
41.37%
17,748,482
17.46%
Cost of revenue
22,026,847
14,075,520
9,486,875
Unusual Expense (Income)
NOPBT
4,423,621
11,015,383
8,261,607
NOPBT Margin
16.72%
43.90%
46.55%
Operating Taxes
1,456,736
1,708,903
1,016,205
Tax Rate
32.93%
15.51%
12.30%
NOPAT
2,966,885
9,306,480
7,245,402
Net income
5,531,261
-8.73%
6,060,057
-14.98%
7,127,629
94.65%
Dividends
(2,072,413)
(2,484,414)
(826,530)
Dividend yield
3.28%
2.17%
1.17%
Proceeds from repurchase of equity
BB yield
Debt
Debt current
7,826,000
8,923,211
2,942,742
Long-term debt
18,573,506
10,194,477
6,581,388
Deferred revenue
(1,063,968)
(68,207)
Other long-term liabilities
128,185
34,045
20,012
Net debt
533,426
(3,819,406)
(6,117,861)
Cash flow
Cash from operating activities
2,106,732
4,004,019
5,952,778
CAPEX
(8,605,246)
(4,955,715)
(1,614,270)
Cash from investing activities
(6,907,735)
(5,930,578)
(4,268,545)
Cash from financing activities
5,318,656
6,266,243
(4,911,983)
FCF
(9,418,950)
2,305,016
6,987,556
Balance
Cash
10,611,497
10,533,094
6,996,991
Long term investments
15,254,583
12,404,000
8,645,000
Excess cash
24,543,557
21,682,549
14,754,567
Stockholders' equity
31,802,134
24,052,669
20,037,410
Invested Capital
35,931,957
21,803,502
13,315,548
ROIC
10.28%
53.00%
53.88%
ROCE
7.30%
24.73%
29.36%
EV
Common stock shares outstanding
41,631
41,631
41,632
Price
1,518.00
-44.80%
2,750.00
62.15%
1,696.00
142.63%
Market cap
63,195,858
-44.80%
114,485,250
62.14%
70,607,872
142.63%
EV
63,775,499
110,813,032
67,272,851
EBITDA
6,291,606
12,615,857
9,439,039
EV/EBITDA
10.14
8.78
7.13
Interest
138,783
125,060
126,646
Interest/NOPBT
3.14%
1.14%
1.53%